NEWS HIGHLIGHTSMedia Articles Related to Rhinocort (Budesonide)
ACAAI: Combo Beats Budesonide Alone in Asthma (CME/CE)
Source: MedPage Today Allergy & Immunology [2009.11.12]
MIAMI BEACH (MedPage Today) -- Regardless of the asthma patient's age, treatment with a combination of budesonide and formoterol produced a greater improvement in lung function than budesonide pressurized metered-dose inhalers alone, researchers reported here.
Treatment Of Allergic Rhinitis Improves Coexisting Diseases
Source: Allergy News From Medical News Today [2009.11.09]
The treatment of allergic rhinitis is shown to improve co-existing conditions including conjunctivitis, asthma, sinusitis, otitis media with effusion (fluid in the middle ear) and sleep disorders according to an international expert at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.
Allergy drug tackles nasal congestion: study (Reuters)
Source: Y! Health Allergy News [2009.11.12]
Reuters - The "second generation" allergy drug desloratadine (brand name Clarinex) significantly reduces both the runny nose and congestion of seasonal and persistent allergic rhinitis, a study shows.
ACAAI: Drug Combo Effective in Allergic Eye Symptoms (CME/CE)
Source: MedPage Today Allergy & Immunology [2009.11.11]
MIAMI BEACH (MedPage Today) -- A combination of two standard drugs delivered together was safe and effective in treating the itchy and watery eyes associated with seasonal allergic rhinitis, a researcher said.
Published Studies Related to Rhinocort (Budesonide)
An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. [2009.09.19]
INTRODUCTION: In budesonide/formoterol (Symbicort(R) Turbuhaler(R), AstraZeneca, Lund, Sweden) maintenance and reliever therapy (SMART), patients with asthma take a daily maintenance dose of budesonide/formoterol, with the option of taking additional doses for symptom relief instead of a short-acting beta(2)-agonist (SABA). This study assesses the cost-effectiveness of SMART compared with usual care in patients with mild-to-moderate persistent asthma treated by general practitioners in the Netherlands from a societal perspective... CONCLUSIONS: Treating primary care patients with mild-to-moderate persistent asthma with SMART instead of ICS plus bronchodilators does not affect health outcomes and does not increase costs; therefore, is likely to be an alternative for guideline-directed treatment, from a health and economic perspective.
Aerosolized L epinephrine vs Budesonide for Postextubation Stridor A Randomized Controlled Trial. [2009.09.03]
Objective: To compare the efficacy and adverse effects of aerosolized Lepinephrine vs budesonide in the treatment of postextubation stridor... However, epinephrine showed a more sustained effect.
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. [2009.09.01]
CONCLUSIONS: Ipilimumab shows activity in advanced melanoma, with encouraging survival and manageable adverse events. Budesonide should not be used prophylactically for grade >or=2 diarrhea associated with ipilimumab therapy.
Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. [2009.07]
Grapefruit juice (GFJ) inhibits CYP3A activity in the gut wall, thereby decreasing first-pass metabolism of CYP3A substrates...
Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing. [2009.07]
BACKGROUND: The goal of asthma therapy is to control symptoms using minimal pharmacologic intervention. OBJECTIVE: To evaluate the efficacy and tolerability of once-daily budesonide/formoterol vs once-daily budesonide in patients stable with twice-daily budesonide/formoterol... CONCLUSIONS: Pulmonary function and asthma control were more effectively maintained with all budesonide/formoterol regimens vs once-daily budesonide and with twice-daily budesonide/formoterol at twice the daily formoterol dose vs both once-daily budesonide/formoterol doses.
Clinical Trials Related to Rhinocort (Budesonide)
Assess the Efficacy and Safety of Rhinocort Aqua [Completed]
The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5
years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and
stuffy noses.
Rhinocort Aqua Versus Placebo and Fluticasone Propionate [Completed]
The purpose of this study is to compare once daily treatment with Rhinocort against placebo
and Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
Adults With Moderate to Severe Asthma [Completed]
A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when
given to asthma patients aged 12 years and above.
New Nasal Applicator / New Formulation - User Study [Completed]
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort
Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving
the symptoms of seasonal allergic rhinitis (SAR).
New Version Pulmicort Turbuhaler USA Children [Completed]
A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently
approved Pulmicort Turbuhaler with a new version of the inhaler, in children and adolescents
who have asthma. In addition the study evaluated the functionality of the new inhaler at the
end of its intended life.
|
